Please use this identifier to cite or link to this item:
https://dspace.uzhnu.edu.ua/jspui/handle/lib/10600
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Готько, Євген Степанович | - |
dc.contributor.author | T. J. Price | - |
dc.contributor.author | A. Cervantès | - |
dc.contributor.author | A. F. Sobrero | - |
dc.contributor.author | M. Ducreux | - |
dc.contributor.author | T. André | - |
dc.contributor.author | E. Chan | - |
dc.contributor.author | F. Lordick | - |
dc.contributor.author | C. J. A. Punt | - |
dc.contributor.author | A. H. Strickland | - |
dc.contributor.author | G. Wilson | - |
dc.contributor.author | T. E. Ciuleanu | - |
dc.contributor.author | L. Roman | - |
dc.contributor.author | E. Van Cutsem | - |
dc.contributor.author | Y. Tian R. Sidhu | - |
dc.contributor.author | M. Peeters | - |
dc.date.accessioned | 2016-11-11T11:01:00Z | - |
dc.date.available | 2016-11-11T11:01:00Z | - |
dc.date.issued | 2014 | - |
dc.identifier.uri | https://dspace.uzhnu.edu.ua/jspui/handle/lib/10600 | - |
dc.description.abstract | Background The study 20050181 demonstrated significant improvements in progression-free survival (PFS), objective response, and a nonsignificant trend toward increased overall survival (OS) with panitumumab– FOLFIRI versus FOLFIRI alone for second-line wild-type (WT) KRAS metastatic colorectal cancer (mCRC). Updated long-term data from a prespecified descriptive analysis are reported. Patients and methods Patients receiving one prior mCRC treatment were randomly assigned (1:1) to panitumumab (6.0 mg/kg)–FOLFIRI versus FOLFIRI every 2 weeks. Co-primary end points (PFS and OS) were prospectively analyzed by tumor KRAS status. Results One thousand one hundred and eighty-six patients were randomly assigned. In patients with WT KRAS tumors, panitumumab–FOLFIRI significantly improved PFS versus FOLFIRI [median 6.7 versus 4.9 months; hazard ratio (HR) 0.82 [95% confidence interval (CI) 0.69, 0.97]; P = 0.023]. A trend toward longer OS was observed (median 14.5 versus 12.5 months; HR 0.92 [95% CI 0.78, 1.10]; P = 0.37). Response rates improved from 10% to 36% (P < 0.0001). From post hoc analyses in patients receiving prior oxaliplatin– bevacizumab, panitumumab–FOLFIRI improved PFS (median 6.4 versus 3.7 months; HR 0.58 [95% CI 0.37, 0.90]; P = 0.014). PFS and OS appeared longer for worst-grade skin toxicity of 2–4, versus 0–1 or FOLFIRI. Safety results were as previously reported and consistent with the known toxicities with anti-epidermal growth factor receptor therapy. Conclusions These data confirm the primary efficacy and safety findings of this trial and support panitumumab– FOLFIRI as a second-line treatment of WT KRAS mCRC | uk |
dc.language.iso | en | uk |
dc.publisher | Ann Oncol. 2014 Jan;25(1):107-16. doi: 10.1093/annonc/mdt523. | uk |
dc.subject | antibody, chemotherapy, FOLFIRI, metastatic colorectal cancer, panitumumab | uk |
dc.title | Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer | uk |
dc.type | Text | uk |
dc.pubType | Стаття | uk |
Appears in Collections: | Наукові публікації кафедри радіології та онкології |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Final_results_from_a_randomized_phase_3_study_of_FOLFIRI_±_panitumumab_for_second-line_treatment_of_metastatic_colorectal_cancer.PDF | 522.8 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.